396 related articles for article (PubMed ID: 7893186)
1. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition.
Knoll J; Miklya I
Arch Int Pharmacodyn Ther; 1994; 328(1):1-15. PubMed ID: 7893186
[TBL] [Abstract][Full Text] [Related]
2. Enhanced catecholaminergic and serotoninergic activity in rat brain from weaning to sexual maturity: rationale for prophylactic (-)deprenyl (selegiline) medication.
Knoll J; Miklya I
Life Sci; 1995; 56(8):611-20. PubMed ID: 7869839
[TBL] [Abstract][Full Text] [Related]
3. (-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.
Knoll J; Yoneda F; Knoll B; Ohde H; Miklya I
Br J Pharmacol; 1999 Dec; 128(8):1723-32. PubMed ID: 10588928
[TBL] [Abstract][Full Text] [Related]
4. (-)Deprenyl and (-)1-phenyl-2-propylaminopentane, [(-)PPAP], act primarily as potent stimulants of action potential-transmitter release coupling in the catecholaminergic neurons.
Knoll J; Miklya I; Knoll B; Markó R; Kelemen K
Life Sci; 1996; 58(10):817-27. PubMed ID: 8602114
[TBL] [Abstract][Full Text] [Related]
5. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
Knoll J
Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
[TBL] [Abstract][Full Text] [Related]
6. Effect of MAO inhibitors on the high-affinity reuptake of biogenic amines in rat subcortical regions.
Tekes K; Magyar K
Neurobiology (Bp); 2000; 8(3-4):257-64. PubMed ID: 11225517
[TBL] [Abstract][Full Text] [Related]
7. A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study.
Miklya I; Knoll B; Knoll J
Life Sci; 2003 Apr; 72(23):2641-8. PubMed ID: 12672509
[TBL] [Abstract][Full Text] [Related]
8. An HPLC tracing of the enhancer regulation in selected discrete brain areas of food-deprived rats.
Miklya I; Knoll B; Knoll J
Life Sci; 2003 May; 72(25):2923-30. PubMed ID: 12697275
[TBL] [Abstract][Full Text] [Related]
9. R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron.
Knoll J
J Neural Transm Suppl; 1987; 25():45-66. PubMed ID: 2828537
[TBL] [Abstract][Full Text] [Related]
10. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons.
Engberg G; Elebring T; Nissbrandt H
J Pharmacol Exp Ther; 1991 Nov; 259(2):841-7. PubMed ID: 1658311
[TBL] [Abstract][Full Text] [Related]
11. The pharmacology of 1-phenyl-2-propylamino-pentane (PPAP), a deprenyl-derived new spectrum psychostimulant.
Knoll J; Knoll B; Török Z; Timár J; Yasar S
Arch Int Pharmacodyn Ther; 1992; 316():5-29. PubMed ID: 1356324
[TBL] [Abstract][Full Text] [Related]
12. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
13. Metabolic transformation of deprenyl enantiomers in rats.
Szökö E; Kalász H; Magyar K
Neurobiology (Bp); 1999; 7(2):247-54. PubMed ID: 10591057
[TBL] [Abstract][Full Text] [Related]
14. Effect of MAO inhibitors on the uptake and metabolism of dopamine in rat and human brain.
Tekes K; Tóthfalusi L; Gaál J; Magyar K
Pol J Pharmacol Pharm; 1988; 40(6):653-8. PubMed ID: 3152003
[TBL] [Abstract][Full Text] [Related]
15. D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.
Muralikrishnan D; Samantaray S; Mohanakumar KP
Synapse; 2003 Oct; 50(1):7-13. PubMed ID: 12872288
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of deprenyl, a selective monoamine oxidase (MAO) B inhibitor in rat: relationship of metabolism to MAO-B inhibitory potency.
Yoshida T; Yamada Y; Yamamoto T; Kuroiwa Y
Xenobiotica; 1986 Feb; 16(2):129-36. PubMed ID: 3083608
[TBL] [Abstract][Full Text] [Related]
17. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
Lamensdorf I; Youdim MB; Finberg JP
J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
[TBL] [Abstract][Full Text] [Related]
18. (-)Deprenyl (Selegiline): past, present and future.
Knoll J
Neurobiology (Bp); 2000; 8(2):179-99. PubMed ID: 11061214
[TBL] [Abstract][Full Text] [Related]
19. Stereoselectivity and isoenzyme selectivity of monoamine oxidase inhibitors. Enantiomers of amphetamine, N-methylamphetamine and deprenyl.
Robinson JB
Biochem Pharmacol; 1985 Dec; 34(23):4105-8. PubMed ID: 3933519
[TBL] [Abstract][Full Text] [Related]
20. The effect of repeated doses of (-) deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline.
Zsilla G; Földi P; Held G; Székely AM; Knoll J
Pol J Pharmacol Pharm; 1986; 38(1):57-67. PubMed ID: 3020531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
